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Rubella is usually a mild disease of childhood characterized 
by rash, lymphadenopathy, low grade fever and leukopenia. The 
major morbidity associated with rubella is the development of 
congenital infection when disease occurs in susceptible pregnant 
women1 • The prevalence and outcome of rubella in susceptible 
solid organ transplant recipients are unknown. This case report 
describes a 13-year-old liver transplant recipient who underwent 
evaluation for fever and adenopathy and was found to have 
rubella. 
CASE REPORT 
A 13-year-old native Argentinian boy who underwent 
orthotopic liver transplantation (OLT) for crigler-Najjar 
Syndrome one year previously presented with a one week history of 
painful cervical lymphadenopathy and low grade fever. His post-
transplant course had been unremarkable. At the time of 
admission he denied any history of rhinorrhea, cough, 
conjunctivitis, sore throat, nausea, vomiting, diarrhea or rash. 
His father reported that the patient had a recent exposure to 
rubella in his school and that he had never been immunized 
against this agent. His medications consisted of florinef, 
trimethoprim-sulfamethoxazole and the experimental 
immunosuppressant FK 506 at an oral dose of 2.5 mg twice daily. 
On admission, the patient was afebrile and well appearing. 
Physical examination revealed multiple right anterior and 
posterior cervical lymph nodes. The largest node was a right 
jugulodigastric node that measured 0.5 x 1.5 cm. A left axillary 
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node was present that measured 1.0 x 0.5 cm. The tonsils were 
normal in size; there was neither erythema or exudate. There was 
no hepatosplenomegaly. The remainder of his physical examination 
was unremarkable. 
The white blood cell count was 4.8 x 103 cells/mm3 with 43% 
neutrophils, 42% lymphocytes, 6% monocytes, 3% eosinophils, 1% 
basophils and 5% atypical lymphocytes; the platelet count was 
121,000/mm3• Serum electrolytes, BUN and creatinine were within 
normal limits. The gamma-glutamyl transferase was slightly 
elevated at 89 IU/L (upper limit normal = 44 IU/L); the remainder 
of the patient's liver injury tests were normal. CT scans of the 
chest and abdomen were normal; no adenopathy was noted. 
The right jugulodigastric lymph node was excised. 
Histologic examination of the lymph node showed reactive changes 
consisting of paracortial expansion without immunoblastic 
changes. Viral cytopathic effects were not seen. 
Titers for Epstein-Barr virus (EBV) obtained both prior to 
and at the time of this admission were consistent with past 
infection without evidence of reactivation or reinfection (VCA-
IgG > 50 with negative titers against VCA-IgM, Early Antigen and 
Nuclear Antigen). A pre-transplant screen for antibodies against 
rubella was negative. Repeat serologies showed IgM antibody > 50 
EUlml and a positive titer for IgG. 
Bacterial and viral cultures of blood and urine were 
negative. Interference assays for rubella using Echovirus 11 
were performed on viral cultures obtained from the lymph node, 
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throat, urine and blood. The assays from both the throat and 
lymph node were positive suggesting the presence of rubella virus 
in these cultures. 
Initial management of this patient consisted of decreasing 
his dose of FK 506 to 2.0 mg twice daily. The patient was 
discharged and followed up as an outpatient when results of his 
serologic tests and lymph node biopsies were known. His 
lymphadenopathy resolved within one month and he continues to do 
well. 
DISCUSSION 
The widespread use of live rubella vaccine in the United 
states has resulted in a markedly decreased incidence of 
rubella2 • However, such vaccination is not routinely practiced 
in many other regions of the world, including Argentina, and in 
these areas clinical rubella remains endemic. The increasing 
incidence of acquired immunodeficiency syndrome in children in 
areas were rubella remains endemic raises concern about the 
potential development of severe disease from this usually mild 
infection. The symptoms experienced by our patient were modest; 
suspicion for rubella was raised by the history of exposure in a 
susceptible individual. Although rubella is classically 
associated with rash, it commonly occurs in 25% - 50% of patients 
without the presence of an exanthem3-5 • Lymphadenopathy is a 
major manifestation of disease, and the low-grade fever and mild 
leukopenia present in our patient are typical. 
Serologic testing is the primary mode of diagnosing rubella. 
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The presence of IgG and IgM antibody in a patient not recently 
vaccinated substantiates a recent rubella infection. The 
diagnosis of rubella is confirmed by viral culture of nasal or 
throat specimens. The presence of rubella infection in cell 
cultures is detected utilizing inoculated African Green Monkey 
Kidney cell cultures that are super infected with echovirus 11 and 
observed for the development of a characteristic cytopathic 
effect6 • The inhibition of the enterovirus-mediated cytopathic 
effect demonstrates the presence of rubella virus. Two specimens 
from our patient demonstrated this interference effect confirming 
the diagnosis of rubella. 
Low-grade fever and lymphadenopathy in a liver transplant 
recipient appropriately initiates an evaluation for the presence 
of EBV-associated post-transplant lymphoproliferative disease 
(PTLD), as well as other viruses or infectious processes which 
may cause lymphadenopathy. PTLD was suspected in this patient 
based upon the timing and clinical presentation and the 
relatively high incidence of PTLD in pediatric OLT recipients 
(4.7%)7. EBV and the resultant PTLD is the most important viral 
infection to occur more than six months after pediatric liver 
transplant. Presentation in OLT patients on cyclosporine 
typically occurs in the first six months to one year after 
transplant, however cases as late as six years post transplant 
have been reported8 • Clinical findings range from exudative 
tonsillitis, adenopathy and fever (as seen in classical 
mononucleosis) to solitary or multiple nodules subsequently 
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diagnosed as lymphoma. The morbidity and mortality associated 
with this process and the relatively high-rate of response to 
withdrawal of immunosuppression mandates confirmation of the 
diagnosis. Review of our experience suggests that outcome is 
improved with earlier recognition, reinforcing the need to react 
promptly in patients with a typical clinical presentation. 
The diagnosis of EBV-associated PTLD was abandoned in our 
patient because imaging procedures showed no abnormalities and 
neither serologic nor histopathologic examinations were 
supportive. If the patient was proven to have PTLD he would 
typically have been treated in the hospital with a minimum of two 
weeks of intravenous acyclovir and withdrawal of 
immunosuppression until the onset of rejection. Instead, the 
patient was discharged after a four day hospitalization on a 
minimally decreased dose of FK 506. 
The presence of lymphadenopathy in the immunocompromised, 
post-transplant patient is compatible with a variety of 
infectious processes. The most frequent and important of these 
is EBV-associated PTLD. other infections, including rubella, cat 
scratch disease (Apalsch A, et ale Ped Inf Dis J. in press)9, 
atypical mycobacteria and other causes of regional or diffuse 
adenopathy may mimic PTLD in presentation. An awareness of the 
differential diagnosis of lymphadenopathy is necessary, 
especially in the pediatric population where non EBV-associated 
conditions may occur. Careful evaluation allow differentiation 
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